FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/10/074947 [Registered on: 08/10/2024] Trial Registered Prospectively
Last Modified On: 25/09/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Clinical trial to evaluate the efficacy Of Mahamasha Oil Karanpooran(eardrops) and Syp.Mashabaladi Kwatha Orally in the management of Tinnitus 
Scientific Title of Study   A RANDOMISED CONTROL CLINICAL TRIAL TO EVALUATE THE EFFICACY OF MAHAMASHA TAILA KARNAPOORNA AND MASHBALADI KWATHA ORALLY IN THE MANAGEMENT OF KARNANADA/TINNITUS 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  DR ASHU 
Designation  PROFESSOR AND HOD  
Affiliation   
Address  SHRI KRISHNA AYUSH UNIVERSITY KURUKSHETRA HARYANA

Kurukshetra
HARYANA
136118
India 
Phone  9416553131  
Fax    
Email  drashukataria@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  DR ASHU 
Designation  PROFESSOR AND HOD  
Affiliation   
Address  SHRI KRISHNA AYUSH UNIVERSITY KURUKSHETRA HARYANA

Kurukshetra
HARYANA
136118
India 
Phone  9416553131  
Fax    
Email  drashukataria@gmail.com  
 
Details of Contact Person
Public Query
 
Name  DR ASHLEKHA SHARMA 
Designation  Ph.D(SCHOLAR) 
Affiliation  saraswati ayurveda hospital and medical college Gharuan  
Address  HOUSE NO.2307 SECTOR 35 CHANDIGARH

Chandigarh
CHANDIGARH
160022
India 
Phone  9988306066  
Fax    
Email  sharmaashlekha@gmail.com  
 
Source of Monetary or Material Support  
SARASWATI AYURVEDIC HOSPITAL AND MEDICAL COLLEGE GHARUAN MOHALI PUNJAB PIN CODE;140413 INDIA  
 
Primary Sponsor  
Name  DR ASHLEKHA SHARMA 
Address  SARASWATI AYURVEDIC HOSPITAL AND COLLEGE GHARUAN MOHALI PUNJAB INDIA PINCODE;140413 
Type of Sponsor  Private hospital/clinic 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DR ASHLEKHA SHARMA  SARASWATI AYURVEDIC HOSPITAL AND COLLEGE GHARUAN   SARASWATI AYURVEDIC COLLEGE AND HOSPITAL GHARUAN MOHALI
Rupnagar
PUNJAB 
09988306066

sharmaashlekha@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
INSTITUTIONAL ETHICS COMMITEE  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:H931||Tinnitus. Ayurveda Condition: KARNA-NADAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: MAHAMASHA TAILAM, Reference: BHAISAJYA RATNAVALI VAAT VYADHI ADHYAYE, Route: Otic, Dosage Form: Taila, Dose: 4(drops), Frequency: od, Bhaishajya Kal: Abhakta, Duration: 1 Months, anupAna/sahapAna: No, Additional Information: -
(2) Medicine Name: MASHABALADI QWATH, Reference: BHAISAJYA RATNAVALI VAAT VYADHI, Route: Oral, Dosage Form: Kwatha/ Kashaya, Dose: 40(ml), Frequency: bd, Bhaishajya Kal: Antarabhakta, Duration: 1 Months, anupAna/sahapAna: Yes(details: -), Additional Information: -
2Comparator Arm (Non Ayurveda)-CAP CAROVERINE
 
Inclusion Criteria  
Age From  16.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1. Patients between age of 16-65 years irrespective of age, sex, caste, religion etc.
2. Patients will selected on the basis of classical signs and symptoms of Karnanada (Tinnitus).
3. Subjective type of tinnitus.
4. Patients willing to be registered for trial. 
 
ExclusionCriteria 
Details  1.Congenital deformity of external/middle ear
2.Blockage due to stenosis of external auditory canal/wax
3.Established diabetes mellitus and hypertension
4.Pregnant and lactating mothers.
5.Cases which required surgical intervention
7. Severe hearing loss and patients not fulfilling the inclusion criteria. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Alternation 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Based upon the
score of THI the classification of severity of tinnitus will be done:
THI SCORE BAND LEVEL OF TINNITUS
 
During the study of 60 days (Trial Treatment duration ) examination of the patient will be done
on 0th, 7th ,30th day and 60th day.
After completing the study of 60 days patient will be reassessed on 75th and
90th day.
Time period of study per patient – 90 days 
 
Secondary Outcome  
Outcome  TimePoints 
A. To access the safety profile of both the drugs.
B. To access the compliance of both the drugs
C. To compile & understand all the latest researches & treatments under trial for tinnitus 
Two months 
 
Target Sample Size   Total Sample Size="102"
Sample Size from India="102" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 1/ Phase 2 
Date of First Enrollment (India)   10/10/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  10/10/2024 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   This is a self financed clinical trial.So no recruitment is required .
I am Ph.D(SCHOLAR) In the field of ayurveda.I am conducting this trial to address a disease as well as a symptom called tinnitus.Ayurvedic interventions has many a times helped many times in cases of tinnitus.The drugs used here are in the form of eardrops as well as oral.Synergistic effect will be evaluated.
 
Close